Abstract
Amiodarone is an iodine rich agent widely used for the treatment of ventricular arrhythmias, paroxysmal supraventricular tachycardia, atrial fibrillation and flutter. However 14-18% of patients treated with amiodarone develop overt thyroid dysfunction in the form of either amiodarone-induced thyrotoxicosis (AIT) or amiodaroneinduced hypothyroidism (AIH). Two different types of AIT have been recognised and designated as Type 1 and Type 2. Distinguishing between the two is often difficult, but necessary for instituting appropriate treatment. We report a case of a 56 year-old male patient who was started on amiodarone for atrial fibrillation and then developed AIT. The challenges in the diagnosis and management of these patients are discussed.
| Original language | English |
|---|---|
| Pages | 319-323 |
| Volume | 9 |
| No. | 3 |
| Specialist publication | Sultan Qaboos University Medical Journal (SQUMJ) |
| Publication status | Published - 2009 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Cardiology (incl Cardiovascular Diseases)
- Metabolic Medicine
Fingerprint
Dive into the research topics of 'A Case of Amiodarone-Induced Thyrotoxicosis: A diagnostic and therapeutic dilemma'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver